de Perrot Marc, Fadel Elie, Mercier Olaf, Mussot Sacha, Chapelier Alain, Dartevelle Philippe
Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Centre Chirurgical Marie-Lannelongue, Le Plessis-Robinson, France.
J Thorac Cardiovasc Surg. 2006 Jan;131(1):81-9. doi: 10.1016/j.jtcvs.2005.07.062. Epub 2005 Dec 5.
We sought to determine whether the benefit warrants the risk in patients undergoing carinal resection for carcinoma.
This was a retrospective single-center study.
Between June 1981 and August 2004, 119 patients underwent carinal resection for carcinoma in our institution. Carinal pneumonectomy was performed in 103 cases (96 right and 7 left pneumonectomies), carinal resection plus right upper lobectomy in 3, carinal resection after left pneumonectomy in 2, and carinal resection without pulmonary resection in 11. Superior vena caval resection was combined with carinal pneumonectomy in 25 patients with bronchogenic carcinoma (13 patients had complete superior vena caval resection with graft interposition). Nine (7.6%) patients died in the hospital or within 30 days of the operation. Follow-up was complete for 117 (98%) patients up to August 2004 or to the date of death. The 5- and 10-year survivals were 44% and 25%, respectively, for patients with bronchogenic carcinoma (n = 100). However, survival was significantly better in patients with N0 or N1 disease (n = 73) than in those with N2 or N3 disease (n = 27; 53% vs 15% at 5 years, respectively). The 5- and 10-year survivals in the remaining 19 patients reached 66% and 48%, respectively, and were best in patients with neuroendocrine carcinoma (100% survival at 10 years) and adenoid cystic carcinoma (69% survival at 10 years).
Surgical intervention for carcinoma involving the carina is feasible, with acceptable mortality and good long-term survival in selected patients. The presence of positive N2 disease should, however, be considered a potential contraindication to carinal resection in patients with bronchogenic carcinoma because of the poor long-term survival.
我们试图确定对于接受隆突切除术治疗癌症的患者,其获益是否大于风险。
这是一项回顾性单中心研究。
1981年6月至2004年8月期间,我院有119例患者接受了隆突切除术治疗癌症。其中103例行隆突全肺切除术(96例右全肺切除术和7例左全肺切除术),3例行隆突切除术加右上叶切除术,2例行左全肺切除术后隆突切除术,11例行隆突切除术但未行肺切除术。25例支气管源性癌患者的上腔静脉切除术与隆突全肺切除术联合进行(13例患者行完全上腔静脉切除术并植入移植物)。9例(7.6%)患者在医院内或术后30天内死亡。截至2004年8月或死亡日期,117例(98%)患者完成了随访。支气管源性癌患者(n = 100)的5年和10年生存率分别为44%和25%。然而,N0或N1期疾病患者(n = 73)的生存率显著高于N2或N3期疾病患者(n = 27;5年生存率分别为53%和15%)。其余19例患者的5年和10年生存率分别达到66%和48%,其中神经内分泌癌患者的生存率最佳(10年生存率为100%),腺样囊性癌患者的生存率为(10年生存率为69%)。
对于累及隆突的癌症,手术干预是可行的,在部分患者中死亡率可接受且长期生存率良好。然而,对于支气管源性癌患者,N2期疾病阳性应被视为隆突切除术的潜在禁忌证,因为其长期生存率较差。